Doxorubicin Hydrochloride Tillomed: Withdrawal of the marketing authorisation application
doxorubicin
Table of contents
Overview
Laboratorios Tillomed Spain S.L.U. withdrew its application for a marketing authorisation of Doxorubicin Hydrochloride Tillomed for the treatment of breast and ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma.
The company withdrew the application on 2 March 2020.
Key facts
Name |
Doxorubicin Hydrochloride Tillomed |
Product number |
EMEA/H/C/005194 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
02/03/2020 |
Company making the application | |
Withdrawal type |
Initial authorisation |
All documents
-
List item
Withdrawal assessment report for Doxorubicin Hydrochloride Tillomed (PDF/948.27 KB)
Adopted
First published: 27/07/2020
EMA/666721/2019 -
List item
Withdrawal letter: Doxorubicin Hydrochloride Tillomed (PDF/265.88 KB)
First published: 27/03/2020 -
List item
Questions and answers on the withdrawal of application for the marketing authorisation of Doxorubicin Hydrochloride Tillomed (doxorubicin hydrochloride pegylated liposomal concentrate for dispersion for infusion, 2 mg/ml) (PDF/132.78 KB)
First published: 27/03/2020
EMA/142714/2020 -
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').